Burning Rock Biotech Limited, a Chinese firm specializing in cancer therapy selection tests, operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. Its focus is on developing next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests across a range of cancer types, including lung, gastrointestinal, and prostate cancer. Offering products such as OncoCompass IO and OncoCompass Target, the company also collaborates with major pharmaceutical firms such as AstraZeneca, Johnson & Johnson, and Merck KGaA to conduct clinical trials and research studies. Alongside this, it has established key partnerships with genomic testing firms Myriad Genetics and Oncocyte Corporation, licensing their products for use in China. Founded in 2014 and based in Guangzhou, Burning Rock Biotech Limited has become a key player in developing cancer screening and treatment technologies.
Brenntag's ticker is BNR
The company's shares trade on the ASX stock exchange
They are based in Perth, Australia
There are 1-10 employees working at Brenntag
It is brenntag.com/corporate/en/about
Brenntag is in the Basic Materials sector
Brenntag is in the Gold industry
The following five companies are Brenntag's industry peers: